ResMed Debt/Equity Ratio 2010-2025 | RMD

ResMed debt/equity ratio for the quarter ending March 31, 2025 was 0.12.

  • ResMed average debt/equity ratio for 2024 was 0.16, a 52.94% decline from 2023.
  • ResMed average debt/equity ratio for 2023 was 0.34, a 17.24% decline from 2022.
  • ResMed average debt/equity ratio for 2022 was 0.29, a 20.83% increase from 2021.

Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.

ResMed Debt/Equity Ratio 2010-2025 | RMD

  • ResMed average debt/equity ratio for 2024 was 0.16, a 52.94% decline from 2023.
  • ResMed average debt/equity ratio for 2023 was 0.34, a 17.24% decline from 2022.
  • ResMed average debt/equity ratio for 2022 was 0.29, a 20.83% increase from 2021.

Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$227.2B
Boston Scientific (BSX)$140.7B
Stryker (SYK)$132.3B
EssilorLuxottica (ESLOY)$128.4B
Medtronic (MDT)$105.9B
Lonza Group Ag (LZAGY)$47.4B
Haleon (HLN)$46.2B
Agilent Technologies (A)$29.2B
GE HealthCare Technologies (GEHC)$28.6B
Terumo (TRUMY)$28.2B
Koninklijke Philips (PHG)$22.2B
Zimmer Biomet Holdings (ZBH)$19.4B
Insulet (PODD)$17.3B
Baxter (BAX)$14.8B
Smith & Nephew SNATS (SNN)$11.4B
Sunny Optical Technology (SNPTF)$7.6B
Lantheus Holdings (LNTH)$6.9B
Bio-Rad Laboratories (BIO)$6.7B
Demant (WILYY)$6.6B
Prestige Consumer Healthcare (PBH)$4B
Shandong Weigao Medical Polymer (SHWGF)$3.5B
Perrigo (PRGO)$3.5B
ICU Medical (ICUI)$3.4B
Haemonetics (HAE)$2.9B
Envista Holdings (NVST)$2.6B
GN Store Nord (GNNDY)$2.2B
LeMaitre Vascular (LMAT)$1.9B
QuidelOrtho (QDEL)$1.7B
AtriCure (ATRC)$1.6B
Kestra Medical Technologies (KMTS)$1.2B